## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.49 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($72.86)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Henry Schein, Inc. (HSIC): A Bull Case Theory**
- Source: Insider Monkey | 20251209T143700 | Bullish | Relevance: 99%
- This article summarizes a bullish thesis on Henry Schein, Inc. (HSIC), highlighting the company's undervalued stock price, near-term catalysts like a new CEO, and growth opportunities such as private-label expansion and AI-driven software. Despite stagnant end-market growth, the company is poised for EPS growth exceeding $7 within two to three years through strategic improvements and a share repurchase program. Investors are encouraged to consider HSIC's robust market position and defensive industry exposure for potential upside.

**2. Henry Schein to renominate KKR designees to board for 2026 term By Investing.com**
- Source: Investing.com UK | 20251209T130400 | Bullish | Relevance: 98%
- Henry Schein, Inc. announced its intention to renominate Max Lin and William K. “Dan” Daniel, both KKR Hawaii Aggregator L.P. designees, to its board of directors for the 2026 annual meeting, with terms expiring in 2027. This decision follows KKR's exercise of an extension election under a Strategic Partnership Agreement. The company also recently reported strong Q3 2025 earnings and expanded its distribution agreement with vVARDIS for Curodont Repair Fluoride Plus in the U.S.

**3. Why Henry Schein (HSIC) Stock Is Up Today**
- Source: The Globe and Mail | 20251210T060833 | Somewhat-Bullish | Relevance: 98%
-  Shares of Henry Schein (NASDAQ:HSIC), a dental and medical products company, rose 2.8% after Barclays initiated coverage with an 'Overweight' rating and an $86 price target. The company also announced an extension of its strategic partnership with KKR. This positive news follows a previous stock gain related to hopes for an interest rate cut from the Federal Reserve.

**4. Henry Schein to renominate KKR designees to board for 2026 term**
- Source: Investing.com | 20251209T132633 | Bullish | Relevance: 98%
-  Henry Schein, Inc. announced its decision to renominate Max Lin and William K. Daniel, both KKR designees, to its board of directors for election at the company's 2026 annual meeting. This move follows KKR Hawaii Aggregator L.P.'s exercise of an extension election under a Strategic Partnership Agreement. The company also reported strong Q3 2025 earnings and an expanded distribution agreement with vVARDIS for Curodont Repair Fluoride Plus.

**5. SVB Wealth LLC Invests $1.42 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251209T142609 | Somewhat-Bullish | Relevance: 98%
-  SVB Wealth LLC acquired a new stake of 19,364 shares in Henry Schein, Inc. (NASDAQ:HSIC) during Q2, valued at approximately $1.42 million. Institutional investors now own about 96.62% of the company's stock, and analysts maintain an average "Hold" rating with a target price of $76.92. Henry Schein recently surpassed quarterly EPS estimates and provided FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +3.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.3% to 1.8% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 at 2.2% confirms short-term momentum alignment. AM_20 at 4.0% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.78% (CS: 57) | Neutral |
| RSI_14 | 65.9 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $76.24
- **Stop Loss:** $72.86 (4.4% risk)
- **Target:** $83.00 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 408
- **Position Value:** $31,105.92
- **Portfolio %:** 31.11%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*